Next Article in Journal
Isolation of A Novel Bacillus thuringiensis Phage Representing A New Phage Lineage and Characterization of Its Endolysin
Next Article in Special Issue
Causes and Consequences of Spatial Within-Host Viral Spread
Previous Article in Journal
Clinical Features of Varicella-Zoster Virus Infection
Previous Article in Special Issue
Non-Uniform and Non-Random Binding of Nucleoprotein to Influenza A and B Viral RNA
Article

Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus

Research Center in Infectious Diseases of the CHU of Québec and Laval University, 2705, Boul. Laurier (RC-709), Québec City, QC G1V 4G2, Canada
*
Authors to whom correspondence should be addressed.
Viruses 2018, 10(11), 610; https://doi.org/10.3390/v10110610
Received: 28 September 2018 / Revised: 29 October 2018 / Accepted: 2 November 2018 / Published: 3 November 2018
(This article belongs to the Special Issue What’s New with Flu?)
Immunosuppressed individuals can shed influenza virus for prolonged periods of time, leading to the frequent emergence of antiviral resistance. We evaluated the benefits of oseltamivir and favipiravir combination therapy compared to single antiviral agents and monitored the emergence of drug-resistant variants in a pharmacologically immunosuppressed mouse model infected with the A(H1N1) pandemic influenza virus. C57BL/6 mice were immunosuppressed with cyclophosphamide and infected with a lethal dose of pandemic influenza A(H1N1) virus. Forty-eight hours post-infection, mice were treated with oseltamivir (20 mg/kg), favipiravir (20 or 50 mg/kg) or both agents BID for 5 or 10 days. Body weight losses, survival rates, lung viral titers, cytokine levels and emergence of resistant viruses were evaluated. Treatment of immunosuppressed mice with high (50 mg/kg) but not low (20 mg/kg) doses of favipiravir in combination with oseltamivir (20 mg/kg) significantly delayed mortality and reduced lung viral titers compared to treatment with a single drug regimen with oseltamivir but did not prevent the emergence of oseltamivir-resistant H275Y neuraminidase variants. Combination therapy with oseltamivir and favipiravir should be considered for evaluation in clinical trials. View Full-Text
Keywords: pandemic influenza virus; immunosuppression; combination therapy; oseltamivir; favipiravir; resistance; mice pandemic influenza virus; immunosuppression; combination therapy; oseltamivir; favipiravir; resistance; mice
Show Figures

Figure 1

MDPI and ACS Style

Baz, M.; Carbonneau, J.; Rhéaume, C.; Cavanagh, M.-H.; Boivin, G. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. Viruses 2018, 10, 610. https://doi.org/10.3390/v10110610

AMA Style

Baz M, Carbonneau J, Rhéaume C, Cavanagh M-H, Boivin G. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. Viruses. 2018; 10(11):610. https://doi.org/10.3390/v10110610

Chicago/Turabian Style

Baz, Mariana; Carbonneau, Julie; Rhéaume, Chantal; Cavanagh, Marie-Hélène; Boivin, Guy. 2018. "Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus" Viruses 10, no. 11: 610. https://doi.org/10.3390/v10110610

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop